Induction of apoptosis in malignant and camptothecin-resistant human cells

Annals of the New York Academy of Sciences

Volumn 803, Issue , 1996, Pages 143-156

  Chatterjee, Devasis ^a   Wyche, James H ^a   Pantazis, Panayotis ^b,c  

^a BROWN UNIVERSITY   (United States)

^b St Joseph's Medical Center Houston   (United States)

^c Stehlin Found for Cancer Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ALKALOID; CAMPTOTHECIN; ETOPOSIDE; SURAMIN;

APOPTOSIS; CELL CYCLE; CELL CYCLE G1 PHASE; CONFERENCE PAPER; DRUG RESISTANCE; FLOW CYTOMETRY; HUMAN; HUMAN CELL;

EID: 0030453592     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb26383.x     Document Type: Conference Paper

References (52)

1. PANTAZIS, P. 1995. The water-insoluble camptothecin analogues: Promising drugs for the effective treatment of haematological malignancies. Leukemia Res. 19: 775-788.
2. PANTAZIS, P. 1995. Water-insoluble camptothecin congeners: Cytotoxicity, development of resistance, and combination treatments. Clin. Cancer Res. 1: 1235-1244.
3. LAROCCA, R. V., C. A. STEIN & C. E. MYERS. 1990. Suramin: Prototype of a new generation of antitumor compounds. Cancer Cells 2: 106-115.
4. LARSEN, A. K. 1993. Suramin: An anticancer drug with unique biological effects. Cancer Chemother. Pharmacol. 32: 96-98.
5. STEIN, C. A. 1993. Suramin: A novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res. 53: 2239-2248.
6. BEHREND, T. N., E. RØNNE & K. DANØ. 1993. Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin. J. Biol. Chem. 268: 5985-5989.
7. SCHER H. I. & W. D. HESTON. 1992. Suramin as an archetypical compound in the development of growth factor antagonists for inhibition of genitourinary tumors. In Therapy for Genitourinary Cancer. H. Lapor & R. K. Lawson, Eds.: 131-151. Klewer Academic Publisher: Norwell, MA.
8. VAN RIJSWIJK, R. E., A. C., VAN LOENEN, J. WAGSTAFF, E. MEIJER, C. J. VAN GROENINGEN, J. J. HEIMANS & H. M. PINEDO. 1992. Suramin: Rapid loading and weekly maintenance regimens for cancer patients. J. Clin. Oncol. 10: 1788-1794.
9. SCHER H. I., D. I. JODRELL, J. M. IVERSEN, T. CURLEY, W. TONG, M. EGORIN & A. FORREST. 1992. Use of adaptive control with feedback to individualize suramin dosing. Cancer Res. 52: 64-70.
10. EWING, M. W., S. C. LIU, J. R. GNARRA, M. C. C. M. WALTHER, C. E. MEYERS & W. M. LINEHAN. 1993. Effect of suramin on the mitogenic response of the human prostate carcinoma cell line PC-3. Cancer 71: 1151-1158.
11. QIAO, L., J. G. PIZZOLO & M. R. MELAMED. 1994. Effects of suramin on expression of proliferation associated nuclear antigens in DU-145 prostate carcinoma cells. Biochem. Biophys. Res. Commun. 201: 581-588.
12. LOPEZ, R., G. J. PETERS, E. SMITSKAMP-WILMS, J. A. VIRIZUELA, J. VAN ARK OTTE, N. M. PINEDO & G. GIACCONE. 1994. In viro sequence-dependent synergistic effect of suramin and camptothecin. Eur. J. Cancer 30A: 1670-1674.
13. REED, J. C. 1994. Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 124: 1-6.
14. MARTIN, S. J. & D. R. GREEN. 1995. Apoptosis and cancer: The failure of controls on cell death and cell survival. Crit. Rev. Oncol./Hematol. 18: 137-153.
15. CAMPOS, L., J-P. ROUAULT, O. SABIDO, P. ORIOL, N. ROUBI, C. VASSELON, E. ARCHIMBAUD, J-P. MAGAUD & D. GUYOTAT. 1993. High expression of bcl-2 protein in acute myeloid leukemic cells is associated with poor response to chemotherapy. Blood 81: 3091-3096.
16. L can confer a multidrug resistance phenotype. Blood 86: 1903-1910.
17. LOTEM, J. & L. SACHS. 1995. Regulation of bcl-2, bcl-X and bax in the control of apoptosis by hematopoietic cytokines and dexamethasone. Cell Growth. & Diff. 6: 647-653.
18. BROONE, N. E., C. M. DARGAN, S. KRAJEWSKI & J. C. REED. 1995. Expression of bcl-2, Bcl-X, and Bax after T cell activation and Il-2 withdrawal. J. Immunol. 155: 2311-2317.
19. OLTVAI, Z., C. L. MILLIMAN & S. J. KORSMEYER. 1993. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619.
20. SATO, T., M. HANADA, S. BODRUG, S. IRIE, N. IWAMA, L. H. BOISE, C. B. THOMPSON, E. GOLEMIS, L. FONG, H-G. WANG & J. C. REED. 1994. Interaction among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system. Proc. Natl. Acad. Sci. USA 91: 9238-9242.
21. YIN, X-M., Z. N. OLTVAI & S. J. KORSMEYER. 1994. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369: 321-323.
22. HAN, Z., D. CHATTERJEE, D. M. HE, J. EARLY, P. PANTAZIS, J. H. WYCHE & E. A. HENDRICKSON. 1995. Evidence for a G2 checkpoint in p53-independent apoptosis induction by X-irradiation. Mol. Cell Biol. 15: 5849-5857.
23. L and Bcl-2 repress a common pathway of cell death. J. Exp. Med. 182: 821-828.
24. PARK, J. R., I. D. BERNSTEIN & D. M. HOCKENBERY. 1995. Primitive human hematopoietic precursors express Bcl-X but not Bcl-2. Blood 86: 868-876.
25. PANTAZIS, P., A. DEJESUS, J. EARLY, R. RODRIGUEZ, D. CHATTERJEE, Z. HAN, J. WYCHE & B. GIOVANELLA. 1995. Development of human leukemia U-937 cell sublines resistant to doxorubicin: Induction of differentiation and altered sensitivities to topoisomerase-directed drugs. Anticancer Res. 15: 1873-1882.
26. PANTAZIS, P., D. CHATTERJEE, Z. HAN, J. WYCHE, A. DEJESUS & B. GIOVANELLA. 1996. Monocytic differentiation and synthesis of proteins associated with apoptosis in human leukemia U-937 cells acquiring resistance to vincristine. Eur. J. Haematol. 57: 79-86.
27. WANG, L., M. M. MIURA, L. BERGERON, H. ZHU & J. YUAN. 1994. Ich-1, an Ice-ced-3-related gene, encodes both positive and negative regulators of programmed cell death. Cell 78: 739-750.
28. WHYTE, M. & G. EVAN. 1995. Apoptosis: The last cut is the deepest. Nature 376: 17-18.
29. TAUPIN, J-L., Q. TIAN, N. KEDERSHA, M. ROBERTSON & P. ANDERSON. 1995. The RNA-binding protein TIAR is translocated from the nucleus to the cytoplasm during Fas-mediated apoptotic cell death. Proc. Natl. Acad. Sci. USA 92: 1629-1633.
30. KAWAKAMI, A., Q. TIAN, X. DUAN, M. STREULI, S. F. SCHLOSSMAN & P. ANDERSON. 1992. Identification and functional characterization of a TIA-1-related nucleosin. Proc. Natl. Acad. Sci. USA 89: 8681-8685.
31. PEEHL, D. M. 1994. The male reproductive system: Prostatic cell lines. In Atlas of Human Tumor Cell Lines. R. J. Hay, J-G. Park & A. Gazdar, Eds.: 387-411. Academic Press: San Diego, CA.
32. PANTAZIS, P., J. T. MENDOZA, A. DEJESUS, E. RUBIN, D. KUFE & B. C. GIOVANELLA. 1994. Partial characterization of human leukemia U-937 cell sublines resistant to 9-nitro-camptothecin. Eur. J. Haematol. 53: 135-144.
33. DARZYNKIEWICZ, Z., S. BRUNO, G. DEL BINO, W. GORCZYCA, M. A. HOLTZ, P. LASSOTA & F. TRAGANOS. 1992. Features of apoptotic cells by flow cytometry. Cytometry 13: 795-808.
34. AFANASYEV, V. N., B. A. KOROL, N. P. MATYLEVICH, V. A. PECHATNIKOV & S. R. UMANSKY. 1993. The use of flow cytometry for the investigation of cell death. Cytometry 14: 603-609.
35. TELFORD, W. G., L. E. KING & P. J. FRAKER. 1994. Rapid quantitation of apoptosis in pure and heterogenous cell populations using flow cytometry. J. Immunol. Method. 172: 1-16.
36. FRANKFURT, O. S., J. J. BYRNES, D. SECKINGER, D. E. V. SUGARBAKER. 1993. Apoptosis (programmed cell death) and the evaluation of chemosensitivity in chronic lymphocytic leukemia and lymphoma. Oncol. Res. 5: 37-42.
37. SCHRIER, S. L. 1994. Internucleosomal cleavage of DNA is insufficient evidence to conclude that cell death is apoptotic. Blood 83: 2005-2006.
38. POMMIER, Y., A. TANIZAWA & K. W. KOHN. 1994. Mechanisms of topoisomerase I inhibition by anticancer drugs. Adv. Pharmacol. 29B: 73-92.
39. LIU, L. F. 1995. Biochemistry of camptothecin. In Camptothecins: New Anticancer Agents. M. Potmesil & H. Pinedo, Eds.: 9-19. CRC Press: Boca Raton, FL.
40. YAMAZAKI, H., A. DILWORTH, C. E. MYERS & B. K. SINHA. 1993. Suramin inhibits DNA damage in human prostate cancer cells treated with topoisomerase inhibitors in vitro. Prostate 23: 25-36.
41. KHALED, Z., D. RIDEOUT, K. R. O'DRISCOLL, D. PETRYLAK, A. CACACE, R. PATEL, L-C. CHIANG, S. ROTENBERG & C. A. STEIN. 1995. Effects of suramin-related and other clinically therapeutic polyanions on protein kinase C activity. Clin. Cancer Res. 1: 113-122.
42. MAHONEY, C., A. AZZI & K. HUANG. 1990. Effects of suramin, an anti-human immunodeficiency virus reverse transcriptase agent, on protein kinase C. J. Biol. Chem. 265: 5424-5428.
43. CODERONI, S., M. PAPARELLI & G. L. GIANFRANCESCHI. 1990. Role of calf thymus DNA-topoisomerase I phosphorylation on relaxation activity expression and on DNA-protein interaction. Role of topoisomerase I phosphorylation. Mol. Biol. Rep. 14: 35-39.
44. SAMUELS, D. S. & N. SHIMIZU. 1992. DNA topoisomerase I phosphorylation in murine fibroblasts treated with 12-0-tetradecanoylphorbol-13-acetate and in vitro by protein kinase C. J. Biol. Chem. 267: 11156-11162.
45. POMMIER, Y., D. KERRIGAN, K. D. HARTMAN & R. I. GLAZER. 1990. Phosphorylation of mammalian DNA topoisomerase I and activation by protein kinase C. J. Biol. Chem. 265: 9418-9422.
46. CARDELLINI, E. & E. DURBAN. 1993. Phosphorylation of human topoisomerase I by protein kinase C in vitro and in phorbol 12-myristate 13-acetate-activated HL-60 promyelocytic leukemia cells. Biochem. J. 291: 303-307.
47. TANIZAWA, A. & Y. POMMIER. 1992. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res. 52: 1848-1854.
48. UTSUGI, T., M-R. MATTERN, C. K. MIRABELLI & N. HANNA. 1990. Potentiation of topoisomerase inhibitor induced DNA strand breakage and cytotoxicity by tumor necrosis factor: Enhancement of topoisomerase activity as a mechanism of potentiation. Cancer Res. 50: 2636-2640.
49. GOLDWASSER, F., I. BAE, M. VALENTI, K. TORRES & Y. POMMIER. 1995. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute Anticancer Screen. Cancer Res. 55: 2116-2121.
50. RUBIN, E., P. PANTAZIS, T. BHARTI, D. TOPPMEYER, B. C. GIOVANELLA & D. KUFE. 1994. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitrocamptothecin. J. Biol. Chem. 269: 2433-2439.
51. COLOMBEL, M., F. SYMMANS, S. GIL, K. M. O'TOOLE, D. CHOPIN, M. BENSON, C. A. OLSSON, S. KORSMEYER & R. BUTTYAN. 1993. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am. J. Pathol. 143: 390-400.
52. RAFFO, A. J., H. PERLMAN, M-W. CHEN, M. L. DAY, J. S. STREITMAN & R. BUTTYAN. 1995. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 55: 4438-4445.